Traders should await the earnings call for actual financial results and clinical development updates. Until then, no actionable data is available.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 19 $1.84entry
- T+1 · 8mo ago +0.54%α +2.29% · $1.85
- T+5 · 8mo ago +29.35%α +31.56% · $2.38
- T+20 · 7mo ago +38.59%α +30.97% · $2.55
- T+60 · 5mo ago +121.74%α +107.40% · $4.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals announced it will host a conference call to discuss its fiscal year 2025 financial results and provide updates on its drug development programs, including NRX-100 and NRX-101. The press release contains no actual financial data, only forward-looking statements and procedural details about the earnings call.
Key Facts
- NRx Pharmaceuticals will host an earnings call on March 24, 2026, to discuss FY2025 results.
- No financial figures (revenue, EPS, etc.) were disclosed in the press release.
- Company highlighted progress in drug development programs and regulatory designations for NRX-100 and NRX-101.
- Forward-looking statements dominate the release; no material financial or operational data provided.
Financial Impact
No financial impact can be assessed, no quantitative results disclosed.
Risk Factors
- Lack of disclosed financials increases uncertainty ahead of the call.
- Forward-looking statements may create expectations that are not met during the actual call.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258835 |
Track record
22 reports on NRXP
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers